Gastric cancer

Updated data from GARNET cohort F evaluating Dostarlimab in mismatch repair-deficient ( dMMR ) non-endometrial advanced solid cancers were presented at...


The FDA ( Food and Drug Administration ) has approved Enhertu ( fam-Trastuzumab Deruxtecan-nxki; fam-Trastuzumab Deruxtecan ) for adult patients...


Acid reflux drugs that are sometimes recommended to ease stomach problems during cancer treatment may have an unintended side effect:...


Despite the broad activity of checkpoint inhibitors across tumor types, primary or secondary resistance after initial response represents a major...


The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, for the...


Pembrolizumab ( Keytruda ) has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to results...


Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation...


Eli Lilly has announced that the FDA ( Food and Drug Administration ) has approved Cyramza ( Ramucirumab ) as...


Vascular endothelial growth factor ( VEGF ) and VEGF receptor-2 ( VEGFR-2 )-mediated signalling and angiogenesis can contribute to the...


The FDA ( Food and Drug Administration ) has approved Ramucirumab ( Cyramza ) in combination with Paclitaxel as a...


Vascular endothelial growth factor ( VEGF ) and VEGF receptor-2 ( VEGFR-2 )-mediated signalling and angiogenesis can contribute to the...


Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced gastric cancer were...


Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced urothelial cancer (...


Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation...


Numerous epidemiologic studies have shown that a diet high in salt is associated with an increased risk of gastric cancer....


In an analysis of the results of interventions to eradicate the bacterium Helicobacter pylori ( a risk factor for gastric...


The FDA ( Food and Drug Administration ) has assigned Priority Review to the regulatory submission for Ramucirumab as a...


The results from the Phase III REGARD trial of Ramucirumab as a single agent in patients with advanced gastric cancer...


There are no agents specifically approved in the United States or European Union for advanced gastric cancer patients. Gastric cancer...


The European Commission has granted marketing authorisation for Tafinlar ( Dabrafenib ) as an oral targeted treatment indicated in monotherapy...